Roberto Botelho

TL;DR: In patients with stable coronary artery disease or low-risk ACS treated with zotarolimus-eluting stents, 3 months of dual antiplatelet therapy was noninferior to 12 months for NACCE, without significantly increasing the risk of stent thrombosis.

TL;DR: The GLOBAL LEADERS trial as discussed by the authors showed that ticagrelor, in combination with aspirin for 1 month, followed by ticaragrelor alone, improves outcomes after percutaneous coronary intervention compared with standard antiplatelet regimens.

TL;DR: In the REMEDEE trial the Combo stent has shown to be effective by meeting the primary noninferiority angiographic endpoint and safe, with an overall low rate of clinical events in both stent groups, including no stent thrombosis up to 12 months.

TL;DR: The DESolve Nx trial as discussed by the authors showed favorable performance of the DESolve scaffold, effective inhibition of neointimal hyperplasia, and for the first time, early luminal and scaffold growth at 6 months with sustained efficacy and safety through 2 years.

TL;DR: Summary Part I - Diagnosis and risk stratification page 1 1.a.